

Sahil Khanna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6041921/publications.pdf>

Version: 2024-02-01

204
papers

6,186
citations

66343

42
h-index

82547

72
g-index

206
all docs

206
docs citations

206
times ranked

6261
citing authors

#	ARTICLE	IF	CITATIONS
1	Composition, diversity and potential utility of intervention-naïve pancreatic cancer intratumoral microbiome signature profiling via endoscopic ultrasound. <i>Gut</i> , 2022, 71, 441-443.	12.1	11
2	Microscopic Colitis and Risk of Colon Adenomas: A Multicenter Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e902-e904.	4.4	4
3	The Epidemiology of Microscopic Colitis in Olmsted County, Minnesota: Population-Based Study From 2011 to 2019. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1085-1094.	4.4	19
4	Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent <i>Clostridioides difficile</i> Infection. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2763-2770.	2.3	15
5	Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in <i>Clostridioides difficile</i> Infection. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 577-583.	4.4	7
6	Transitions of care in <i>Clostridioides difficile</i> infection: a need of the hour. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210786.	3.2	2
7	An Important Mimicker. <i>Gastroenterology</i> , 2022, 162, 1840-1843.	1.3	1
8	Durable reduction of <i>Clostridioides difficile</i> infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. <i>BMC Infectious Diseases</i> , 2022, 22, 245.	2.9	38
9	<i>Clostridioides difficile</i> infection: curbing a difficult menace. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210899.	3.2	1
10	Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile From a Population-Based Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 1311-1315.	0.4	12
11	RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent <i>Clostridioides difficile</i> Infections. <i>Clinical Infectious Diseases</i> , 2021, 73, e1613-e1620.	5.8	27
12	Durability of Response to Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence in Patients With <i>Clostridioides difficile</i> Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e1706-e1712.	5.8	8
13	Fecal Microbiota Transplantation Is Safe and Effective in Patients With <i>Clostridioides difficile</i> Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1627-1634.	4.4	24
14	SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, 2132-2140.	5.8	96
15	Microbiome-based Therapies for Multidrug-resistant Pathobionts: Getting a Step Closer!. <i>Clinical Infectious Diseases</i> , 2021, 72, 1448-1449.	5.8	0
16	Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. <i>Gastroenterology</i> , 2021, 160, 183-192.e3.	1.3	113
17	Fecal Microbiota Transplantation: Tales of Caution. <i>Clinical Infectious Diseases</i> , 2021, 72, e881-e882.	5.8	18
18	Defending against a difficult <i>Clostridioides</i> with a vaccine. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 157-158.	9.1	1

#	ARTICLE	IF	CITATIONS
19	Predictors of failure after fecal microbiota transplantation for recurrent <i>Clostridioides difficile</i> infection: a systematic review and meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1383-1392.	2.9	22
20	Novel risk factors and outcomes in inflammatory bowel disease patients with <i>Clostridioides difficile</i> infection. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199779.	3.2	6
21	Safety of fecal microbiota transplantation for <i>Clostridioides difficile</i> infection focusing on pathobionts and SARS-CoV-2. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110096.	3.2	10
22	Immune response against <i>Clostridioides difficile</i> and translation to therapy. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110148.	3.2	8
23	Advances in <i>Clostridioides difficile</i> therapeutics. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1067-1070.	4.4	1
24	Gut microbiome and <i>Clostridioides difficile</i> infection: a closer look at the microscopic interface. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199473.	3.2	31
25	Efficacy of oral vancomycin prophylaxis for prevention of <i>Clostridioides difficile</i> infection: a systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199404.	3.2	12
26	RISK FACTORS FOR OUTCOMES OF PATIENTS WITH HISTOLOGICALLY PROVEN CHECKPOINT-INHIBITOR COLITIS. <i>Gastroenterology</i> , 2021, 160, S49-S50.	1.3	0
27	Stool banking for fecal microbiota transplantation: ready for prime time?. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 110-112.	1.5	6
28	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of <i>Clostridioides difficile</i> Infection. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 650-668.	1.3	7
29	Neutralization of Fecal Aerosol-Laden SARS CoV-2: Public Health Implications. <i>Mayo Clinic Proceedings</i> , 2021, 96, 818-819.	3.0	0
30	74-Year-Old Woman With Chronic Diarrhea. <i>Mayo Clinic Proceedings</i> , 2021, 96, 770-775.	3.0	1
31	Microbiota restoration for recurrent <i>Clostridioides difficile</i> : Getting one step closer every day!. <i>Journal of Internal Medicine</i> , 2021, 290, 294-309.	6.0	10
32	A defined microbiome therapeutic prevents recurrent <i>Clostridioides difficile</i> . <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 255-256.	8.1	0
33	Outcomes in Patients with SARS-CoV-2 and <i>Clostridioides difficile</i> Coinfection. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1645-1648.	2.7	20
34	The interplay of SARS-CoV-2 and <i>Clostridioides difficile</i> infection. <i>Future Microbiology</i> , 2021, 16, 439-443.	2.0	24
35	Sa611 INTERIM ANALYSIS OF A PHASE 3 OPEN-LABEL STUDY INDICATES SAFETY AND EFFICACY OF RBX2660, AN INVESTIGATIONAL LIVE BIOTHERAPEUTIC, IN A "REAL-WORLD" POPULATION OF PATIENTS WITH RECURRENT <i>CLOSTRIDIoidES DIFFICILE</i> INFECTION. <i>Gastroenterology</i> , 2021, 160, S-573.	1.3	5
36	Fr246 THE NATURAL COURSE OF HISTOLOGICAL CHANGES IN MICROSCOPIC COLITIS. <i>Gastroenterology</i> , 2021, 160, S-277.	1.3	0

#	ARTICLE	IF	CITATIONS
37	Su305 ENDOSCOPIC ULTRASOUND FOR PANCREAS INTRATUMORAL MICROBIOME SIGNATURE PROFILING: COMPOSITION, DIVERSITY, AND POTENTIAL UTILITY. <i>Gastroenterology</i> , 2021, 160, S-667-S-668.	1.3	0
38	Fr249 THE EPIDEMIOLOGY OF MICROSCOPIC COLITIS BETWEEN 2011-2019: AN OLMSTED COUNTY, MINNESOTA POPULATION-BASED STUDY. <i>Gastroenterology</i> , 2021, 160, S-278.	1.3	1
39	Fr632 EVALUATION OF BODY MASS INDEX AND NEUROPSYCHIATRIC DISEASES IN OFFSPRING BORN TO MOTHERS WITH PERIPARTUM CLOSTRIDIODES DIFFICILE INFECTION. <i>Gastroenterology</i> , 2021, 160, S-384.	1.3	0
40	Postinfection Irritable Bowel Syndrome Following Clostridioides difficile Infection. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	2.2	2
41	Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. <i>Gastroenterology</i> , 2021, 160, 1961-1969.e3.	1.3	59
42	Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication. <i>PLoS ONE</i> , 2021, 16, e0252399.	2.5	13
43	Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1418-1425.	3.0	11
44	In reply—Lack of Marked Association Between Gastrointestinal Symptoms and COVID-19 Mortality: An Updated Meta-analysis Based on Adjusted Effect Estimates. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1680-1681.	3.0	1
45	ID: 3518327 PANCREAS INTRA-TUMORAL MICROBIOME COMPOSITION AND DIVERSITY SIGNATURE PROFILING BY ENDOSCOPIC ULTRASOUND ANATOMIC LOCATION. <i>Gastrointestinal Endoscopy</i> , 2021, 93, AB254.	1.0	0
46	Management of Clostridioides difficile infection in patients with inflammatory bowel disease. <i>Intestinal Research</i> , 2021, 19, 265-274.	2.6	23
47	My Treatment Approach to Clostridioides difficile Infection. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2192-2204.	3.0	12
48	Gut microbiota: a target for intervention in obesity. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1169-1179.	3.0	11
49	Reply. <i>Gastroenterology</i> , 2021, 161, 1345.	1.3	0
50	The interplay of Clostridioides difficile infection and inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110202.	3.2	13
51	Predictors and Management of Failed Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 542-547.	2.2	18
52	Medication use and microscopic colitis: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1209-1215.	3.7	17
53	Kinetics of polymerase chain reaction positivity in patients with Clostridioides difficile infection. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110504.	3.2	0
54	Gut microbiome and checkpoint inhibitor colitis. <i>Intestinal Research</i> , 2021, 19, 360-364.	2.6	14

#	ARTICLE	IF	CITATIONS
55	Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children. Clinical Gastroenterology and Hepatology, 2020, 18, 612-619.e1.	4.4	81
56	Reply to Lagier et al. Clinical Infectious Diseases, 2020, 70, 2454-2455.	5.8	0
57	Clostridium difficile Infection in the Emergency Department. Journal of Clinical Gastroenterology, 2020, 54, 350-355.	2.2	7
58	Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1415-1420.	1.9	31
59	Mo1951 REPORTING OF RANDOMIZED CONTROLLED TRIAL METHODOLOGICAL CHARACTERISTICS OF FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR RECURRENT CLOSTRIDIODES DIFFICILE INFECTION (RCDI). Gastroenterology, 2020, 158, S-990-S-991.	1.3	1
60	844 MEDICATION USE AND MICROSCOPIC COLITIS: A MULTICENTER RETROSPECTIVE COHORT STUDY. Gastroenterology, 2020, 158, S-170.	1.3	1
61	Mo1950 HETEROGENEITY OF RANDOMIZED CONTROLLED TRIALS OF FECAL MICROBIOTA TRANSPLANTATION (FMT) IN RECURRENT CLOSTRIDIODES DIFFICILE INFECTION: A SYSTEMATIC REVIEW. Gastroenterology, 2020, 158, S-990.	1.3	1
62	Incidence of Clostridioides difficile infection in peripartum women: a retrospective cohort study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094262.	3.2	1
63	Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2020, 95, 1632-1648.	3.0	95
64	Mo1942 OUTCOMES OF CLOSTRIDIODES DIFFICILE INFECTION IN SURGICAL PATIENTS: RESULTS FROM NATIONAL INPATIENT SAMPLE. Gastroenterology, 2020, 158, S-986-S-987.	1.3	0
65	Tu1797 MANAGEMENT OF PATIENTS WITH HISTOLOGICALLY PROVEN CHECKPOINT-INHIBITOR COLITIS. Gastroenterology, 2020, 158, S-1165.	1.3	1
66	Gut Involvement by COVID-19. Mayo Clinic Proceedings, 2020, 95, 2309-2311.	3.0	1
67	Sa1008 INCIDENCE OF CLOSTRIDIODES DIFFICILE INFECTION FROM 2006-2017: RESULTS FROM THE ROCHESTER EPIDEMIOLOGY PROJECT. Gastroenterology, 2020, 158, S-239-S-240.	1.3	0
68	The Integrative Human microbiome project: a mile stone in the understanding of the gut microbiome. Expert Review of Gastroenterology and Hepatology, 2020, 14, 639-642.	3.0	11
69	37 FECAL MICROBIOTA TRANSPLANTATION IS HIGHLY EFFECTIVE IN REAL-WORLD PRACTICE: INITIAL RESULTS FROM THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION FECAL MICROBIOTA TRANSPLANTATION NATIONAL REGISTRY. Gastroenterology, 2020, 158, S-14-S-15.	1.3	5
70	Tu1793 BILE ACID MALABSORPTION AND OUTCOMES AFTER TREATMENT WITH COLESEVELAM IN MICROSCOPIC COLITIS. Gastroenterology, 2020, 158, S-1163-S-1164.	1.3	2
71	Mo1794 FECAL MICROBIOTA TRANSPLANTATION FOR C. DIFFICILE INFECTION IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology, 2020, 158, S-923.	1.3	0
72	Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era. American Journal of Gastroenterology, 2020, 115, 971-974.	0.4	27

#	ARTICLE	IF	CITATIONS
73	Response to “Comments on the published systematic review and meta-analysis on the increasing antibiotic resistance in <i>Clostridioides difficile</i> ” by Kouhsari et al.. Anaerobe, 2020, 61, 102148.	2.1	0
74	Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?. PLoS ONE, 2020, 15, e0231258.	2.5	5
75	Fecal microbiota transplantation for treatment of patients with recurrent <i>Clostridioides difficile</i> infection. Expert Review of Anti-Infective Therapy, 2020, 18, 669-676.	4.4	15
76	Update on Treatment of <i>Clostridioides difficile</i> Infection. Mayo Clinic Proceedings, 2020, 95, 758-769.	3.0	31
77	Therapies to modulate gut microbiota: Past, present and future. World Journal of Gastroenterology, 2020, 26, 777-788.	3.3	52
78	Gut-Brain Axis and its Neuro-Psychiatric Effects: A Narrative Review. Cureus, 2020, 12, e11131.	0.5	9
79	Mo1889 CORRELATION OF EARLY INFLIXIMAB LEVELS WITH SHORT TERM OUTCOMES IN STEROID REFRACTORY ULCERATIVE COLITIS: A PILOT STUDY. Gastroenterology, 2020, 158, S-964-S-965.	1.3	1
80	Clostridial vaccines in the pipeline. Drugs of the Future, 2020, 45, 653.	0.1	0
81	S0193 Outcomes of Pediatric Hospital and Community-Associated <i>Clostridioides difficile</i> Infection. American Journal of Gastroenterology, 2020, 115, S68-S68.	0.4	0
82	Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent <i>Clostridium difficile</i> Infection: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2019, 68, 1351-1358.	5.8	137
83	Fecal microbiota transplantation for the treatment of recurrent and severe <i>Clostridium difficile</i> infection in solid organ transplant recipients: A multicenter experience. American Journal of Transplantation, 2019, 19, 501-511.	4.7	101
84	Mo1954 “ Fecal Microbiota Transplantation is Safe and Effective for the Treatment of <i>Clostridium Difficile</i> Infection in Patients with Liver Cirrhosis. Gastroenterology, 2019, 156, S-898-S-899.	1.3	2
85	Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis. Lung, 2019, 197, 593-599.	3.3	8
86	Increasing antibiotic resistance in <i>Clostridioides difficile</i> : A systematic review and meta-analysis. Anaerobe, 2019, 58, 35-46.	2.1	41
87	624 “ Comparison of Two Open-Label Trials Demonstrates Similar 6-Month Outcomes for Rbx2660 and Rbx7455” Investigational Microbiota Restoration Therapeutics Administered by Enema Or Oral Capsules for Preventing Recurrent <i>Clostridium Difficile</i> Infections. Gastroenterology, 2019, 156, S-130-S-131.	1.3	1
88	Mo1923 “ Long-Term Safety of Fecal Microbiota Transplantation in the Treatment of Recurrent <i>Clostridioides Difficile</i> Infection. Gastroenterology, 2019, 156, S-888.	1.3	0
89	Tu1880 “ Durable Freedom from <i>Clostridium Difficile</i> Infection Recurrence and Microbiome Restoration During Six-Month Follow-Up For a Phase 1 Clinical Trial of Rbx7455? An Investigational Room Temperature-Stable, Oral Microbiota-based Therapeutic. Gastroenterology, 2019, 156, S-1158.	1.3	2
90	Trends in the Incidence and Outcomes of <i>Clostridioides difficile</i> infection in Hematologic Cancers: A Nationwide Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S357-S358.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Mo1939 “ Peripartum Clostridioides Difficile Infection and Its Effect on Pregnancy and Neonatal Outcomes: A Retrospective Cohort Study. Gastroenterology, 2019, 156, S-892-S-893.	1.3	0
92	Mo1952 “ Efficacy of Oral Vancomycin Prophylaxis for Prevention of Clostridioides Difficile Infection: A Systematic Review and Meta-Analysis. Gastroenterology, 2019, 156, S-897-S-898.	1.3	2
93	Mo1960 “ Corticosteroids and Adverse Outcomes in Inflammatory Bowel Disease Patients with Clostridium Difficile Infections: A Systematic Review and Meta-Analysis. Gastroenterology, 2019, 156, S-901-S-902.	1.3	0
94	Treatment of Recurrent Clostridium difficile Infection”Reply. JAMA - Journal of the American Medical Association, 2019, 321, 513.	7.4	1
95	Management of Clostridioides difficile colitis: insights for the gastroenterologist. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481984765.	3.2	18
96	Reply to Khoruts and Sadowsky. Clinical Infectious Diseases, 2019, 69, 2233-2234.	5.8	1
97	Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review. Clinical Microbiology and Infection, 2019, 25, 958-963.	6.0	66
98	Current and future trends in clostridioides (clostridium) difficile infection management. Anaerobe, 2019, 58, 95-102.	2.1	20
99	In Search of the (Clostridium difficile) Holy Grail. Clinical Infectious Diseases, 2019, 70, 1094-1095.	5.8	4
100	2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World Journal of Emergency Surgery, 2019, 14, 8.	5.0	102
101	2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection. Open Forum Infectious Diseases, 2019, 6, S841-S841.	0.9	0
102	Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360, 2019, 1, .	1.1	2
103	2019 Efficacy of Fecal Microbiota Transplantation for Acute Graft Versus Host Disease in the Gut: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2019, 114, S123-S123.	0.4	1
104	P1.16-01 Complications Associated with Lung Biopsies in Patients with Lung Cancer: A Population Based Analysis. Journal of Thoracic Oncology, 2019, 14, S585.	1.1	0
105	Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 270-274.	1.3	25
106	Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflammatory Bowel Diseases, 2019, 25, 610-619.	1.9	15
107	The Impact of Clostridium difficile Infection on Mortality in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2019, 53, 127-133.	2.2	26
108	Efficacy of Fecal Microbiota Transplant in Hematological Cancers Patients with Recurrent Clostridioides Difficile Infection: A Systemic Review and Meta-Analysis. Blood, 2019, 134, 5870-5870.	1.4	1

#	ARTICLE	IF	CITATIONS
109	119â€fKinetics of Stool Polymerase Chain Reaction in Clostridioides difficile Infection and Its Utility in Predicting Recurrence. American Journal of Gastroenterology, 2019, 114, S71-S72.	0.4	1
110	Fecal microbiota transplant via colonoscopy may be preferred due to intraprocedure findings. Intestinal Research, 2019, 17, 434-437.	2.6	4
111	Trends in the incidence and outcomes of Clostridioides difficile infection in hematological cancers: A nationwide analysis.. Journal of Clinical Oncology, 2019, 37, e18244-e18244.	1.6	0
112	120â€fMicroscopic Colitis and Risk of Colon Adenomas: A Multicenter Retrospective Cohort Study. American Journal of Gastroenterology, 2019, 114, S72-S72.	0.4	0
113	2824â€fInpatient Fecal Microbiota Transplantation for the Treatment of Refractory Severe-Complicated Clostridioides difficile Infection. American Journal of Gastroenterology, 2019, 114, S1557-S1557.	0.4	0
114	756â€fNovel Risk Factors and Outcomes in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. American Journal of Gastroenterology, 2019, 114, S441-S442.	0.4	0
115	Reply to Davido et al. Clinical Infectious Diseases, 2018, 66, 483-485.	5.8	0
116	Do tetracyclines have the potential to reduce the risk of Clostridium difficile infection?. Expert Review of Anti-Infective Therapy, 2018, 16, 183-185.	4.4	2
117	Presence of immune deficiency increases the risk of hospitalization in patients with norovirus infection. Diagnostic Microbiology and Infectious Disease, 2018, 90, 300-306.	1.8	5
118	Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660â€”A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Clinical Infectious Diseases, 2018, 67, 1198-1204.	5.8	96
119	Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2018, 52, 151-154.	2.2	35
120	Donor Screening Experience for Fecal Microbiota Transplantation in Patients With Recurrent C. difficile Infection. Journal of Clinical Gastroenterology, 2018, 52, 146-150.	2.2	50
121	Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis. Clinical Infectious Diseases, 2018, 66, 514-522.	5.8	51
122	Nonâ€“Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 528-533.	4.4	23
123	Microbiota Replacement Therapies: Innovation in Gastrointestinal Care. Clinical Pharmacology and Therapeutics, 2018, 103, 102-111.	4.7	49
124	The Role of Anchoring in Working Up Diarrhea: A Practical Teaching Case. Gastroenterology, 2018, 154, 498-499.	1.3	0
125	1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study. Open Forum Infectious Diseases, 2018, 5, S562-S563.	0.9	0
126	Microbiota replacement for Clostridium difficile by capsule is as effective as via colonoscopy. Journal of Thoracic Disease, 2018, 10, S1081-S1083.	1.4	6

#	ARTICLE	IF	CITATIONS
127	<i>Clostridioides difficile</i> uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	128
128	Statin use and the risk of <i>Clostridium difficile</i> infection: a systematic review with meta-analysis. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 405-416.	2.7	7
129	Diagnosis and Treatment of <i>Clostridium difficile</i> Infection. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1031.	7.4	31
130	Trends in Outcomes of Patients With Metastatic Cancer Undergoing Intubation and Mechanical Ventilation: Results of the National Hospital Discharge Survey. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 286-292.	4.9	5
131	Screening for <i>Clostridium difficile</i> colonization on admission to a hematopoietic stem cell transplant unit may reduce hospital-acquired <i>C. difficile</i> infection. <i>American Journal of Infection Control</i> , 2018, 46, 459-461.	2.3	18
132	Acute kidney injury impact on inpatient mortality in <i>Clostridium difficile</i> infection: A national propensity-matched study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1227-1233.	2.8	14
133	Outcomes of <i>Clostridium difficile</i> Infection in Patients With Obesity: A Nationwide Analysis. <i>American Journal of Gastroenterology</i> , 2018, 113, S121-S122.	0.4	2
134	Risk Factors of <i>Clostridium Difficile</i> Infection in Hematopoietic Stem Cell Transplant Recipients: A Systemic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 4704-4704.	1.4	0
135	Management of <i>Clostridium difficile</i> Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 166-174.	4.4	109
136	Systematic review with meta-analysis: the impact of <i>Clostridium difficile</i> infection on the short- and long-term risks of colectomy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1011-1020.	3.7	34
137	Efficacy and safety of ridinilazole compared with vancomycin for the treatment of <i>Clostridium difficile</i> infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 735-744.	9.1	91
138	Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent <i>Clostridium Difficile</i> Infection: Results from Punch CD 2, A Randomized Doubleblind Placebo-Controlled Trial. <i>Gastroenterology</i> , 2017, 152, S46-S47.	1.3	3
139	Changes in microbial ecology after fecal microbiota transplantation for recurrent <i>C. difficile</i> infection affected by underlying inflammatory bowel disease. <i>Microbiome</i> , 2017, 5, 55.	11.1	118
140	Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With <i>Clostridium difficile</i> Infection: A Nationwide Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 466-472.	4.9	22
141	Association of Gastric Acid Suppression With Recurrent <i>Clostridium difficile</i> Infection. <i>JAMA Internal Medicine</i> , 2017, 177, 784.	5.1	120
142	<i>Clostridium difficile</i> infection: Updates in management. <i>Indian Journal of Gastroenterology</i> , 2017, 36, 3-10.	1.4	6
143	Surotomycin versus vancomycin in adults with <i>Clostridium difficile</i> infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3462-3470.	3.0	57
144	Fecal Microbiota Transplantation for Recurrent <i>Clostridium difficile</i> Infection Reduces Recurrent Urinary Tract Infection Frequency. <i>Clinical Infectious Diseases</i> , 2017, 65, 1745-1747.	5.8	110

#	ARTICLE	IF	CITATIONS
145	The Microbiome in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 481-492.	2.2	45
146	Experience and Outcomes at a Specialized <i>Clostridium difficile</i> Clinical Practice. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2017, 1, 49-56.	2.4	17
147	Outcomes in Patients with Recurrent <i>Clostridium Difficile</i> Infection Treated with Vancomycin Taper. <i>Gastroenterology</i> , 2017, 152, S348.	1.3	4
148	The incidence and outcomes from <i>Clostridium difficile</i> infection in hospitalized adults with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1240-1247.	1.5	20
149	Safety and Efficacy of Fecal Microbiota Transplant for Recurrent <i>Clostridium difficile</i> Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1617-1624.	3.0	53
150	Fecal Microbiota Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 102.	7.4	115
151	Tetracyclines are Associated with a Reduced Risk of <i>Clostridium difficile</i> Infection: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2017, 4, S384-S384.	0.9	0
152	RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent <i>Clostridium difficile</i> , and May Rehabilitate Patient Microbiomes: Open Label Trial Results. <i>Open Forum Infectious Diseases</i> , 2017, 4, S535-S535.	0.9	5
153	Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders. <i>Open Forum Infectious Diseases</i> , 2017, 4, S538-S538.	0.9	1
154	Testing for <i>Clostridium difficile</i> in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, 344-344.	2.5	0
155	Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent <i>Clostridium Difficile</i> Infection is Associated with More Pronounced Alterations in Microbiome Profile. <i>Open Forum Infectious Diseases</i> , 2017, 4, S387-S387.	0.9	1
156	Adherence to Treatment Guidelines for Incident <i>Clostridium difficile</i> Infection in Critically Ill Adults. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
157	Efficacy and Safety of RBX2660 for the Prevention of Recurrent <i>Clostridium difficile</i> Infection: Results. of the PUNCH CD 2 Trial. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	9
158	<i>Clostridium difficile</i> infection after restorative proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis. <i>Colorectal Disease</i> , 2016, 18, O154-7.	1.4	10
159	Repeat <i>Clostridium difficile</i> Testing. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2422.	7.4	21
160	Mo1656 Outcomes of Fidaxomicin Treatment of <i>Clostridium difficile</i> Infection. <i>Gastroenterology</i> , 2016, 150, S744.	1.3	3
161	New-Onset Microscopic Colitis in an Ulcerative Colitis Patient After Fecal Microbiota Transplantation. <i>American Journal of Gastroenterology</i> , 2016, 111, 751-752.	0.4	25
162	Gut microbiome predictors of treatment response and recurrence in primary <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 715-727.	3.7	94

#	ARTICLE	IF	CITATIONS
163	Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 176-176.	3.7	0
164	High risk of postinfectious irritable bowel syndrome in patients with <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 576-582.	3.7	89
165	Hemolyzed blood as a clue to the diagnosis of abdominal pain. <i>Internal and Emergency Medicine</i> , 2016, 11, 609-610.	2.0	1
166	Outcomes in children with <i>Clostridium difficile</i> infection: results from a nationwide survey. <i>Gastroenterology Report</i> , 2016, 4, gow007.	1.3	13
167	A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent <i>Clostridium difficile</i> Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 173-181.	4.0	277
168	Clinical implications of antibiotic impact on gastrointestinal microbiota and <i>Clostridium difficile</i> infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1145-1152.	3.0	30
169	Epidemiology, outcomes, and predictors of mortality in hospitalized adults with <i>Clostridium difficile</i> infection. <i>Internal and Emergency Medicine</i> , 2016, 11, 657-665.	2.0	37
170	Body Mass Index Changes After Fecal Microbiota Transplant for Recurrent <i>Clostridium difficile</i> Infection. <i>American Journal of Gastroenterology</i> , 2016, 111, S103.	0.4	2
171	Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent <i>Clostridium</i> Infection in Patients with Hematologic Malignancies. <i>Blood</i> , 2016, 128, 3599-3599.	1.4	0
172	Letter: anti-CTLA-4-associated colitis and inflammatory bowel disease pathogenesis - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1032-1033.	3.7	1
173	WSES guidelines for management of <i>Clostridium difficile</i> infection in surgical patients. <i>World Journal of Emergency Surgery</i> , 2015, 10, 38.	5.0	78
174	Systematic review: colitis associated with anti-CTLA-4 therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 406-417.	3.7	227
175	Ipilimumab-induced colitis in patients with metastatic melanoma. <i>Melanoma Research</i> , 2015, 25, 321-327.	1.2	44
176	Palmar-plantar erythrodysesthesia. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212434.	0.5	4
177	Ipilimumab-associated colitis or refractory <i>Clostridium difficile</i> infection?. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015211160.	0.5	10
178	Community-acquired <i>Clostridium difficile</i> infection: an increasing public health threat. <i>Infection and Drug Resistance</i> , 2014, 7, 63.	2.7	169
179	1620Extraintestinal <i>Clostridium difficile</i> infections: A Single Center Experience. <i>Open Forum Infectious Diseases</i> , 2014, 1, S433-S433.	0.9	0
180	<i>Clostridium difficile</i> infection: management strategies for a difficult disease. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 72-86.	3.2	38

#	ARTICLE	IF	CITATIONS
181	Clinical predictors of recurrent <i>Clostridium difficile</i> infection in outpatients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 518-522.	3.7	26
182	Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2014, 307, R608-R620.	1.8	25
183	A Clinician's Primer on the Role of the Microbiome in Human Health and Disease. <i>Mayo Clinic Proceedings</i> , 2014, 89, 107-114.	3.0	187
184	Extraintestinal <i>Clostridium difficile</i> Infections: A Single-Center Experience. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1525-1536.	3.0	34
185	Outcomes from Rectal Vancomycin Therapy in Patients With <i>Clostridium difficile</i> Infection. <i>American Journal of Gastroenterology</i> , 2014, 109, 924-925.	0.4	10
186	The Epidemiology of Microscopic Colitis in Olmsted County From 2002 to 2010: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 838-842.	4.4	98
187	Clinical Factors Associated With Development of Severe-Complicated <i>Clostridium difficile</i> Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1466-1471.	4.4	60
188	Appendectomy Is Not Associated With Adverse Outcomes in <i>Clostridium difficile</i> Infection: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 626-627.	0.4	12
189	The Epidemiology of <i>Clostridium difficile</i> Infection in Children: A Population-Based Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 1401-1406.	5.8	182
190	Acute Kidney Injury is an Independent Marker of Severity in <i>Clostridium difficile</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 481-484.	2.2	18
191	Outcomes of Patients With Microscopic Colitis Treated With Corticosteroids: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 256-259.	0.4	62
192	The Epidemiology of Community-Acquired <i>Clostridium difficile</i> Infection: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2012, 107, 89-95.	0.4	518
193	"Community-Acquired <i>Clostridium difficile</i> Infection: An Emerging Entity". <i>Clinical Infectious Diseases</i> , 2012, 55, 1741-1742.	5.8	18
194	Epstein-Barr virus-associated nephrotic syndrome. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 50-52.	2.9	10
195	An Evaluation of Repeat Stool Testing for <i>Clostridium difficile</i> Infection by Polymerase Chain Reaction. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 846-849.	2.2	35
196	Gastric Acid Suppression and Outcomes in <i>Clostridium difficile</i> Infection: A Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2012, 87, 636-642.	3.0	60
197	<i>Clostridium difficile</i> Infection in Patients With Chronic Kidney Disease. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1046-1053.	3.0	70
198	<i>Clostridium difficile</i> Infection: New Insights Into Management. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1106-1117.	3.0	117

#	ARTICLE	IF	CITATIONS
199	Poor outcomes after <i>Clostridium difficile</i> infection in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 307-308.	17.8	34
200	Outcomes in community-acquired <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 613-618.	3.7	71
201	Esophageal vascular ectasia. <i>Endoscopy</i> , 2011, 43, E281-E281.	1.8	3
202	Immunopathogenesis of juvenile dermatomyositis. <i>Muscle and Nerve</i> , 2010, 41, 581-592.	2.2	41
203	52-Year-Old Woman With Dysphagia. <i>Mayo Clinic Proceedings</i> , 2010, 85, 760-763.	3.0	0
204	The growing incidence and severity of <i>Clostridium difficile</i> infection in inpatient and outpatient settings. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 409-416.	3.0	142